Radionuclide ligand conjugates (RLCs) have emerged as a powerful therapeutic and theranostic platform in oncology, with clinical validation achieved in prostate-specific membrane antigen- and somatostatin receptor-directed settings. Yet the field now faces a p... ...

请注册登录后继续浏览